Phase 3 Lymphoma Trial, Recruiting NCT05595447 Sponsor: Hospital Regional de Alta Especialidad del Bajio Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT05595447
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have Hodgkin lymphoma that has come back or stopped responding to ABVD chemotherapy, and whose condition is considered high risk
  • People aged 18 to 90 years old
  • People whose liver is working well enough, based on specific blood test results being within acceptable ranges
  • People whose kidneys are working well enough, based on specific blood test results being within acceptable ranges
  • People whose overall physical health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
  • Women who could become pregnant must have a negative pregnancy test before joining
  • People who have read and signed the informed consent form agreeing to take part

Who may not be able to join:

  • People who choose to withdraw from the study
  • People who develop serious side effects rated as severe or life-threatening (grade 3 or 4) according to a specific medical rating scale used in the trial
  • People who are lost to follow-up, meaning the trial team is no longer able to contact or monitor them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lauro Amador Medina, Hospital regional Alta especialidad Bajío

Phone: 4772697907

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Hospital Regional de Alta Especialidad del Bajio
Registry
ClinicalTrials.gov
Start date
18 October 2022
Est. completion
18 October 2025

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov